672 related articles for article (PubMed ID: 28170391)
21. Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: A cost-effectiveness analysis.
Devine A; Parmiter M; Chu CS; Bancone G; Nosten F; Price RN; Lubell Y; Yeung S
PLoS Negl Trop Dis; 2017 May; 11(5):e0005602. PubMed ID: 28542194
[TBL] [Abstract][Full Text] [Related]
22. Genotypes and phenotypes of G6PD deficiency among Indonesian females across diagnostic thresholds of G6PD activity guiding safe primaquine therapy of latent malaria.
Satyagraha AW; Sadhewa A; Panggalo LV; Subekti D; Elyazar I; Soebianto S; Mahpud N; Harahap AR; Baird JK
PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009610. PubMed ID: 34270547
[TBL] [Abstract][Full Text] [Related]
23. Operational feasibility of Plasmodium vivax radical cure with tafenoquine or primaquine following point-of-care, quantitative glucose-6-phosphate dehydrogenase testing in the Brazilian Amazon: a real-life retrospective analysis.
Brito M; Rufatto R; Murta F; Sampaio V; Balieiro P; Baía-Silva D; Castro V; Alves B; Alencar A; Duparc S; Grewal Daumerie P; Borghini-Fuhrer I; Jambert E; Peterka C; Edilson Lima F; Carvalho Maia L; Lucena Cruz C; Maciele B; Vasconcelos M; Machado M; Augusto Figueira E; Alcirley Balieiro A; Menezes A; Ataídes R; Batista Pereira D; Lacerda M
Lancet Glob Health; 2024 Mar; 12(3):e467-e477. PubMed ID: 38365417
[TBL] [Abstract][Full Text] [Related]
24. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial.
Taylor WRJ; Thriemer K; von Seidlein L; Yuentrakul P; Assawariyathipat T; Assefa A; Auburn S; Chand K; Chau NH; Cheah PY; Dong LT; Dhorda M; Degaga TS; Devine A; Ekawati LL; Fahmi F; Hailu A; Hasanzai MA; Hien TT; Khu H; Ley B; Lubell Y; Marfurt J; Mohammad H; Moore KA; Naddim MN; Pasaribu AP; Pasaribu S; Promnarate C; Rahim AG; Sirithiranont P; Solomon H; Sudoyo H; Sutanto I; Thanh NV; Tuyet-Trinh NT; Waithira N; Woyessa A; Yamin FY; Dondorp A; Simpson JA; Baird JK; White NJ; Day NP; Price RN
Lancet; 2019 Sep; 394(10202):929-938. PubMed ID: 31327563
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of G6PD deficiency and submicroscopic malaria parasites carriage in malaria hotspot area in Northwest, Tanzania.
Manjurano A; Lyimo E; Kishamawe C; Omolo J; Mosha J; Donald M; Kazyoba P; Kapiga S; Changalucha J
Malar J; 2023 Dec; 22(1):372. PubMed ID: 38062464
[TBL] [Abstract][Full Text] [Related]
26. Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens.
IMPROV Study Group
BMC Infect Dis; 2015 Dec; 15():558. PubMed ID: 26643116
[TBL] [Abstract][Full Text] [Related]
27. Risk of hemolysis in Plasmodium vivax malaria patients receiving standard primaquine treatment in a population with high prevalence of G6PD deficiency.
Liu H; Zeng W; Malla P; Wang C; Lakshmi S; Kim K; Menezes L; Yang Z; Cui L
Infection; 2023 Feb; 51(1):213-222. PubMed ID: 35976559
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of G6PD Viangchan variant in malaria endemic areas in Lao PDR: an implication for malaria elimination by 2030.
Ong KIC; Iwagami M; Araki H; Khattignavong P; Soundala P; Keomalaphet S; Prasayasith P; Lorpachan L; Xangsayalath P; Pongvongsa T; Hongvanthong B; Brey PT; Kano S; Jimba M
Malar J; 2019 Mar; 18(1):75. PubMed ID: 30866940
[TBL] [Abstract][Full Text] [Related]
29. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Rodrigo C; Rajapakse S; Fernando D
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD010458. PubMed ID: 32892362
[TBL] [Abstract][Full Text] [Related]
30. Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Lacerda MVG; Llanos-Cuentas A; Krudsood S; Lon C; Saunders DL; Mohammed R; Yilma D; Batista Pereira D; Espino FEJ; Mia RZ; Chuquiyauri R; Val F; Casapía M; Monteiro WM; Brito MAM; Costa MRF; Buathong N; Noedl H; Diro E; Getie S; Wubie KM; Abdissa A; Zeynudin A; Abebe C; Tada MS; Brand F; Beck HP; Angus B; Duparc S; Kleim JP; Kellam LM; Rousell VM; Jones SW; Hardaker E; Mohamed K; Clover DD; Fletcher K; Breton JJ; Ugwuegbulam CO; Green JA; Koh GCKW
N Engl J Med; 2019 Jan; 380(3):215-228. PubMed ID: 30650322
[TBL] [Abstract][Full Text] [Related]
31. Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine.
Galappaththy GN; Tharyan P; Kirubakaran R
Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD004389. PubMed ID: 24163057
[TBL] [Abstract][Full Text] [Related]
32. Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, non-inferiority trial.
Taylor WR; Olupot-Olupot P; Onyamboko MA; Peerawaranun P; Weere W; Namayanja C; Onyas P; Titin H; Baseke J; Muhindo R; Kayembe DK; Ndjowo PO; Basara BB; Bongo GS; Okalebo CB; Abongo G; Uyoga S; Williams TN; Taya C; Dhorda M; Tarning J; Dondorp AM; Waithira N; Fanello C; Maitland K; Mukaka M; Day NJP
Lancet Infect Dis; 2023 Apr; 23(4):471-483. PubMed ID: 36462528
[TBL] [Abstract][Full Text] [Related]
33. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Llanos-Cuentas A; Lacerda MV; Rueangweerayut R; Krudsood S; Gupta SK; Kochar SK; Arthur P; Chuenchom N; Möhrle JJ; Duparc S; Ugwuegbulam C; Kleim JP; Carter N; Green JA; Kellam L
Lancet; 2014 Mar; 383(9922):1049-58. PubMed ID: 24360369
[TBL] [Abstract][Full Text] [Related]
34. Kinetics of glucose-6-phosphate dehydrogenase (G6PD) activity during Plasmodium vivax infection: implications for early radical malaria treatment.
Dahuron L; Goungounga J; Drame M; Douine M; Nacher M; Blaise T; Mosnier E; Musset L; Fouillet M; Djossou F; Epelboin L
Malar J; 2024 May; 23(1):140. PubMed ID: 38725027
[TBL] [Abstract][Full Text] [Related]
35. Effect of primaquine standard dose (15 mg/day for 14 days) in the treatment of vivax malaria patients in Thailand.
Buchachart K; Krudsood S; Singhasivanon P; Treeprasertsuk S; Phophak N; Srivilairit S; Chalermrut K; Rattanapong Y; Supeeranuntha L; Wilairatana P; Brittenham G; Looareesuwan S
Southeast Asian J Trop Med Public Health; 2001 Dec; 32(4):720-6. PubMed ID: 12041544
[TBL] [Abstract][Full Text] [Related]
36. Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study.
Devine A; Battle KE; Meagher N; Howes RE; Dini S; Gething PW; Simpson JA; Price RN; Lubell Y
PLoS Med; 2021 Jun; 18(6):e1003614. PubMed ID: 34061843
[TBL] [Abstract][Full Text] [Related]
37. Chloroquine-Primaquine versus Chloroquine Alone to Treat Vivax Malaria in Afghanistan: An Open Randomized Superiority Trial.
Awab GR; Imwong M; Bancone G; Jeeyapant A; Day NPJ; White NJ; Woodrow CJ
Am J Trop Med Hyg; 2017 Dec; 97(6):1782-1787. PubMed ID: 29141719
[TBL] [Abstract][Full Text] [Related]
38. The mystery of 'saturation gap' and falsely normal G6PD: a case of primaquine-induced haemolysis in Plasmodium vivax malaria infection.
Tang ASO; Soo XY; Yeo ST; Mansor NA; Chew LP; Chua HH
J R Coll Physicians Edinb; 2021 Jun; 51(2):146-148. PubMed ID: 34131671
[TBL] [Abstract][Full Text] [Related]
39. Management of relapsing Plasmodium vivax malaria.
Chu CS; White NJ
Expert Rev Anti Infect Ther; 2016 Oct; 14(10):885-900. PubMed ID: 27530139
[TBL] [Abstract][Full Text] [Related]
40. Glucose-6-phosphate dehydrogenase deficiency prevalence and genetic variants in malaria endemic areas of Colombia.
Valencia SH; Ocampo ID; Arce-Plata MI; Recht J; Arévalo-Herrera M
Malar J; 2016 May; 15(1):291. PubMed ID: 27225440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
